1 Min Read
Jan 31 (Reuters) - AbbVie Inc : * Says expects FDA to grant priority review to hepatitis c drugs * Says expects FDA to act on hepatitis c drug applications within 8 months or
sooner after receiving them
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.